A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113

Trial Profile

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results (n=67) from NCT01449461 and NCT02094573 studies analysing the association between brigatinib efficacy and ALK mutation status using plasma specimens from the initiation of brigatinib treatment and the end of brigatinib treatment , presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 26 May 2017 Planned End Date changed from 1 Sep 2015 to 8 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top